Moderna Inc. announced late on Monday that the Therapeutic Goods Administration (TGA), the agency in charge of medication regulation in Australia, has provisionally authorised their mRNA COVID-19 vaccine, Spikevax, for use in children under the age of six months to five years.
According to a second statement issued by the TGA, the vaccination has been conditionally licenced in the country for those aged six years and older and as a booster dosage for those aged 18 years and older.
The action comes as Australia fights a massive viral epidemic that is being driven by the highly transmissible novel Omicron subvariants, BA.4 and BA.5. Hospital admissions have surpassed record levels in numerous states as a result of the outbreak.
Authorities in this nation anticipate millions of new illnesses and are encouraging people to wear masks inside. However, they have ruled out the implementation of any stringent restrictions in an effort to control the disease’s spread.
In the last week, Argentina and Canada have also given their stamp of approval to the COVID-19 vaccine that Moderna has developed for children aged six months to five years.